Selecta Biosciences, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Selecta Biosciences, Inc. (NASDAQ:SELB) is a clinical-stage biopharmaceutical company that develops precision immune tolerance therapies using its proprietary ImmTOR platform to mitigate unwanted immune responses in autoimmune diseases, gene therapies, and biologic treatments; the platform enables antigen-specific tolerogenic therapies, including ImmTOR-IL which combines ImmTOR with engineered Treg-selective IL-2 for enhanced tolerance magnitude and durability. The company targets applications across immunotherapy for autoimmune disorders, enabling redosing of gene therapies like those for rare diseases, and amplifying efficacy of biologic therapies such as enzyme replacements; its pipeline includes candidates like SEL-212 for gout, SEL-403 for kidney disorders and autoimmune conditions, and SEL-178 for cancer immunotherapy. Founded in 2008 and headquartered in Watertown, Massachusetts, Selecta operates primarily in the United States with a focus on clinical-stage development and strategic partnerships. In November 2023, Selecta completed a reverse merger with Cartesian Therapeutics, Inc., adopting RNAC as the new ticker symbol while retaining Carsten Brunn, Ph.D. as President and CEO, accompanied by a $60.25 million private investment led by board member Timothy A. Springer, Ph.D., resulting in over $110 million in cash to advance Cartesian's mRNA-engineered CAR-T cell therapies (rCAR-T) for autoimmune diseases including Descartes-08 in Phase 2b for myasthenia gravis; subsequent updates in 2025 include FDA Special Protocol Assessment agreement in January for a pivotal trial and cash reserves of approximately $214 million as of late 2024 to fund operations into mid-2027.
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
4 Hot Penny Stocks To Watch With News This Week
Selecta Biosciences, Inc. (SELB) Q4 2022 Earnings Call Transcript
Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week
The 7 Best Biotech Stocks to Buy for February 2023
Selecta: Despite Challenges, Dissolve Topline Data Could Move The Stock
Selecta Biosciences, Inc. (SELB) Q3 2022 Earnings Call Transcript
What The Stock Market Did Today & Top Penny Stocks To Watch Now
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape
Selecta Biosciences, Inc's (SELB) CEO Carsten Brunn on Q2 2022 Results - Earnings Call Transcript
Selecta Biosciences to Participate in Upcoming Investor Conferences